Guangji Wang1,2,3, Bin Kong1,2,3, Yu Liu1,2,3, He Huang1,2,3. 1. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. 2. Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei, China. 3. Hubei Key Laboratory of Cardiology, Wuhan, Hubei, China.
Abstract
BACKGROUND: Left atrial appendage closure (LAAC) using the LAmbre device has been associated with prevention of stroke in patients with nonvalvular atrial fibrillation (AF). Here, we interrogated the long-term safety and efficacy of using the LAmbre device in percutaneous LAAC. METHODS: We analyzed 56 records of patients with nonvalvular AF undergoing LAAC procedures with the LAmbre device. We collected and analyzed the data to define the safety and efficacy of the LAmbre device implantation. RESULT: The LAAC was successfully occluded in the 56 patients. Our data showed no serious residual leak or pericardial effusion occurred during the perioperative period. At a mean follow-up of 37.8 ± 23.5 months, there were 7.1%, 3.6%, and 3.6% rates of death, stroke, and device-related thrombus, respectively. There were no cases of severe residual leak or systemic embolism. CONCLUSION: Taken together, we demonstrate that execution of LAAC with the LAmbre device has high procedural success and prevents AF-related stroke. However, further large-scale trials might be required to confirm our findings.
BACKGROUND: Left atrial appendage closure (LAAC) using the LAmbre device has been associated with prevention of stroke in patients with nonvalvular atrial fibrillation (AF). Here, we interrogated the long-term safety and efficacy of using the LAmbre device in percutaneous LAAC. METHODS: We analyzed 56 records of patients with nonvalvular AF undergoing LAAC procedures with the LAmbre device. We collected and analyzed the data to define the safety and efficacy of the LAmbre device implantation. RESULT: The LAAC was successfully occluded in the 56 patients. Our data showed no serious residual leak or pericardial effusion occurred during the perioperative period. At a mean follow-up of 37.8 ± 23.5 months, there were 7.1%, 3.6%, and 3.6% rates of death, stroke, and device-related thrombus, respectively. There were no cases of severe residual leak or systemic embolism. CONCLUSION: Taken together, we demonstrate that execution of LAAC with the LAmbre device has high procedural success and prevents AF-related stroke. However, further large-scale trials might be required to confirm our findings.
Authors: Shaojie Chen; K R Julian Chun; Stefano Bordignon; Felix K Weise; Takahiko Nagase; Laura Perrotta; Fabrizio Bologna; Boris Schmidt Journal: J Cardiol Date: 2018-12-21 Impact factor: 3.159
Authors: David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick Journal: Lancet Date: 2009-08-15 Impact factor: 79.321
Authors: Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes Journal: J Am Coll Cardiol Date: 2017-11-04 Impact factor: 24.094
Authors: Marina Urena; Josep Rodés-Cabau; Xavier Freixa; Jacqueline Saw; John G Webb; Mélanie Freeman; Eric Horlick; Mark Osten; Albert Chan; Jean-Francois Marquis; Jean Champagne; Réda Ibrahim Journal: J Am Coll Cardiol Date: 2013-05-09 Impact factor: 24.094
Authors: Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann Journal: Heart Rhythm Date: 2017-05-31 Impact factor: 6.343
Authors: Lucas V A Boersma; Boris Schmidt; Timothy R Betts; Horst Sievert; Corrado Tamburino; Emmanuel Teiger; Evgeny Pokushalov; Stephan Kische; Thomas Schmitz; Kenneth M Stein; Martin W Bergmann Journal: Eur Heart J Date: 2016-01-27 Impact factor: 29.983